Sorivudine
From Wikipedia, the free encyclopedia
Sorivudine
|
|
Systematic (IUPAC) name | |
5-[(E)-2-bromoethenyl]-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione | |
Identifiers | |
CAS number | |
ATC code | J05 |
PubChem | |
Chemical data | |
Formula | C11H13BrN2O6 |
Mol. mass | 349.14 g/mol |
Synonyms | BV-araU,Bromovinyl araU,5-Bromovinyl-araU |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | Viral thymidine kinase |
Half life | ? |
Excretion | kidney |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | oral |
Sorivudine (INN) chemical name (E)-5-(2-Bromovinyl)- 1β-D-arabinofuranosyluracil, is a thymine analogue antiviral drug, marketed under trade names such as Usevir (Nippon Shoji,Eisai) and Brovavir (BMS).
Contents |
[edit] Pharmacology
[edit] Feature
- First-line treatment of herpes drug acyclovir was (Zovirax, Activir) from VZV strong activity of the virus.
- Superior gastrointestinal absorption, absorption from the gastrointestinal tract after the most degrading without being excreted as urine.
[edit] Mechanism of action
- Sorivudine is phosphorylated by thymidine kinase activity in the body and is absorbed into the virus's DNA, to inhibit viral DNA replication of DNA polymerase to make it fail to inhibit viral growth.
[edit] Microbiology
Sorivudine is active against most species in the herpesvirus family.
- Herpes simplex virus type I (HSV-1)
- Varicella zoster virus (VZV)
- Epstein-Barr virus (EBV)
|